Company CVAbout Deccan Health Care Ltd 
Deccan Health Care Ltd
Micro Cap
Pharmaceuticals & Drugs
Deccan Health Care Limited was originally incorporated as a Public Limited Company at Hyderabad, Andhra Pradesh on June 14, 1996. The certificate of Commencement of Business was granted on July 03, 1996. Subsequently, the Company was converted into Private Limited Company on June 12, 2009. Further, the Company was converted into Public Company and name of the Company was changed to "Deccan Health Care Limited" on August 31, 2017.
Company Coordinates
Company Details
247 2nd Flr Dwarakapuri Colony, Punjagutta Hyderabad Telangana : 500082
Registrar Details
Bigshare Services Pvt Ltd , E-2 , Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Andheri (E), Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 20.98 Cr
Number of Shares
2.1 Cr
Face Value
INR 10.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
12-Jul-2024
2.1
20.98
604333
10
Conversion of Warrants
12-Oct-2023
2.04
20.38
3333000
10
Preferential basis
13-Jun-2022
1.7
17.04
1329750
10
Preferential basis
31-Dec-2018
1.57
15.71
4212000
10
Public Issues
28-Dec-2018
1.15
11.50
-2000000
10
Offer For Sale
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Minto Purshotam Gupta (13.06%)
Highest Public shareholder
Focal Ventures Private Limited (10.02%)
Individual Investors Holdings
48.92%
Board of Directors
Management
Designation
Remuneration
Minto Gupta
Chairman & Managing Director
30.0 lacs
Meenakshi Gupta
Director
18.0 lacs
Ruchi Khattar
Independent Director
0
Kandlakunta Samhitha
Independent Director
0
Ravi Ram Prasad
Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
Raw Material Consumed
23.3865
0%
Raw Material Consumed
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
R & D Income
1.65
4.18%
Product Development & Approval Charges
0.00
0.00%
R & D Income
R & D Income
Product Development & Approval Charges
Stock DNARevenue and Profits:
Net Sales:
20 Cr
(Quarterly Results - Dec 2024)
Net Profit:
0 Cr
Pharmaceuticals & Drugs
INR 44 Cr (Micro Cap)
36.00
33
0.00%
-0.01
1.56%
0.42
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
